God-dag-mann-økseskaft

Du fikk nok du også ser jeg.

mvh

Når på fredag skal Bergenbio presentere utviklingen av sin fase 2 studie på fredag?

Natt til fredag norsk tid. Tror det er 0250

Date/Time: Friday 29[th] January 2021 at 09.50 Singapore Time / 02.50 CET

The presentation will be available on BerGenBio’s website from 29 January
2021.

YØH
God dag mann økseskaft. Tror du lever i en alt for forenklet verden. Langsiktighet lønner seg skriver du. Akkurat som det er en generell universal regel. Fortell Nano aksjonærer som kjøpte Nano til 100 for 4 år siden hvor happy de er med sin langsiktighet. Nå kan den kjøpes til 14. Det som gjelder i aksjemarkedet er å vurdere risiko, mer eller mindre kontinuerlig. Jo bedre man er til det jo bedre gjør man det i aksjemarkedet. Bare spør Spetalen.

Takk for svar blir spennende å høre hva dem sier der da

Det er som å diskutere med en stein

Synes de har blitt flinke til å legge ut videoer fra presentasjoner fortløpende. Det gir godt inntrykk. Mange selskap holder lukkede presentasjoner for utvalgte investorer, der samtalene ikke deles med resten av investorene. Modernas samtaler med slike lukkede investorgrupper har jo blitt gjenstand for omtale de siste månedene.

Jeg registrerte meg for å være deltager på presentasjonen, men fikk ikke lenke til videofeed. Er det noen av dere andre som fikk det?

Har ikke registrert meg men det er vel bare å se den på hjemmesiden på fredags morgen

Du liker ikke å tape en diskusjon skjønner jeg.

Sa havren til bukken. Tiden vil vise hvem som har tapt denne diskusjonen. God natt!

For dere som ikke har registrert dere eller har fått tilgang :
Jeg har fått link og sjekket kvalitet på streaming, men du får tilsendt en egen personlig epost med link til seminarene om påmeldingen din blir akseptert.

Full fokus på natt til Fredag og presentasjonen - varer kun i 10 minutter

https://library.iaslc.org/conference-program?product_id=20&author=&category=&date=&session_type=&session=&presentation=&keyword=bemcentinib&cme=undefined&;;


Trykk+ på flg link:

+
OA01 - Established Drugs in Special Populations and New Drugs in Established Populations
09:15 - 10:15
1/29/2021
Location: Scientific Program Auditorium
IASLC CME Accredited
Type: Oral
Track: Immunotherapy (Phase II/III Trials)

og da dukker denne 10 minutter presentasjonen opp:


OA01 - Established Drugs in Special Populations and New Drugs in Established Populations
09:15 - 10:15 ( Singapore time)
1/29/2021
Location: Scientific Program Auditorium
IASLC CME Accredited
Type: Oral
Track: Immunotherapy (Phase II/III Trials)
-
OA01.07 - A Phase II Study of the Oral Selective AXL Inhibitor Bemcentinib with Pembrolizumab in Patients with Advanced NSCLC
09:50 - 10:00 | Presenting Author(s): Matthew G. Krebs

Abstract
Introduction
AXL is a mediator of resistance to immunotherapy and a negative prognostic factor for NSCLC. Bemcentinib (BGB324), a first-in-class, oral, selective and potent AXL kinase inhibitor, enhances checkpoint inhibitor (CPI) efficacy in pre-clinical models through tumor-immune mechanisms. Increasingly, the combination of doublet chemotherapy with checkpoint inhibitors (Chemo-CPI) is a commonly used option for advanced NSCLC, and recurrence following such first line therapy represents an area of great unmet need. BGBC008 addresses the unmet need for NSCLC patients who fail 1L SOC.
Methods
BGBC008 is a PhII single-arm, 2-stage study with bemcentinib (200mg/d) and pembrolizumab (200 mg/q3wk) for previously-treated Stage IV lung adenocarcinoma comprising 3 cohorts: chemotherapy-failed IO-naïve patients (post-Chemo), patients progressing on prior CPI therapy (post-CPI monotherapy) and platinum-doublet chemotherapy in combination with pembrolizumab (post-Chemo-CPI). Primary endpoint was ORR according to RECIST1.1 with pre-defined criteria to proceed from the first to second stage in each cohort. Secondary endpoints included DCR, PFS, OS and safety. Exploratory endpoints include biomarker analysis and correlation with clinical endpoints, including composite (tumor and immune cell) cAXL score, PD-L1 TPS, and genome-wide mutational and transcriptome analyses.
Results
As of August 2020, enrollment in the post-Chemo cohort and stage 1 of the post-CPI monotherapy cohort is completed. Results of the post-Chemo cohort (n=50) and post-CPI monotherapy stage 1 cohort (n=16) were previously presented. Stage 2 of the post-CPI monotherapy cohort and stage 1 of the post-Chemo-CPI cohort are currently recruiting into the study.
In patients treated to date, common TEAEs (>25% of patients) for NSCLC patients receiving the bemcentinib + pembrolizumab combination were: increased ALT (29%; 10% G3+), AST (29%; 5% G3+), and diarrhoea (29%; 1% G3+). All cases of treatment-related transaminase increase were reversible and managed with concomitant administration of steroids and treatment interruption.
Having previously demonstrated a very high clinical benefit rate in post-Chemo and post-CPI monotherapy (stage 1) in cAXL-positive patients (73% and 85%, respectively), and low probability of clinical benefit in cAXL-negative patients (40% and 0%, respectively) further focus on the predictive value of cAXL in second line patients following either CPI monotherapy or Chemo-CPI relapse will be reported, together with transcriptional analysis to identify gene based predictive signatures.
Conclusion
Overall, bemcentinib in combination with pembrolizumab was well-tolerated and shows promising clinical activity in relapsed lung cancer. The key unmet need population of second line patients refractory to CPI monotherapy or Chemo-CPI will be presented together with translational data. Clinical Trial Registration: NCT03184571

Se oppdatert 24.01.2021: Gogle Search NCT03184571


https://www.centerwatch.com/clinical-trials/listings/120520/lung-cancer-metastatic-bemcentinib-bgb324-combination-pembrolizumab/

Takk! :-)

Jeg har ingenting mot deg som person focuss. Kanskje hadde vi hatt verdens hyggeligste samtale om vi møttes over kaffe. Når man diskuterer på et forum som dette, så har noen en agenda, andre henger ikke med i samtalen, noen er paranoide osv.
Jeg har forstått at du har mange spørsmål om risiko knyttet til BerGenBio, og at du kanskje synes at for mange er for positive i forhold til det du er. Men alle her vet at det er risiko med BerGenBio, liksom det er risiko i andre selskap. Om du ikke vil høre på noe av det vi andre skriver, så burde du i hvert fall lest presentasjoner og sett gjennom videoene på hjemmesiden til BGBIO (det gjelder alle, ikke bare deg). Det er tungt å sette seg inn i i starten, men når du etter hvert forstår hvordan virkningsmekanismene henger sammen, så gjør det kanskje også noe med risikovurderingen din. Det betyr ikke at risikoen forsvinner, men at du kanskje føler deg tryggere på om dette er rett investering for deg.
Ha en super kveld videre!

Skulle bare mangle - når du spør.... :-)

Fikk flg: epost ikveld :

Welcome to the first worldwide virtual IASLC World Conference on Lung Cancer.

Registrants will receive two emails each day of the WCLC: this evening Virtual Platform Tips email, which will provide tips on how to maximize the virtual experience and easily navigate the platform; and the morning WCLC News email, which will provide coverage of select presentations and posters.

The virtual platform is host to numerous options for interacting with faculty, other attendees, and industry. Much like in a physical convention center, the virtual space is complete with a lobby and signage with each day’s program easily identifiable.

Given that this year’s meeting was supposed to take place in Singapore, the timing of the meeting does center around that time zone. The two plenaries per day are being held at times that were thought to work most broadly around the world. The Program At A Glance is viewable in time zones for Singapore, New York, San Francisco, and Vienna.
After signing in with the same email address that you used to register for the meeting, you can navigate through the platform by clicking on the name of each room or by using the navigation bar at the bottom which will remain in position as you move through the meeting.


Step into the Scientific Program Auditorium to view:

Live broadcasted sessions of the IASLC CME accredited program.
IASLC non-CME accredited Live and On-Demand content.
Satellite CME Symposium.
Presentations from the IASLC Distinguished Service Award and Lectureship Award Winners.
Update from IASLC President Tetsuya Mitsudomi and IASLC CEO Dave Mesko.
More than 1,500 posters are available for viewing in the ePoster Hall. You can access the Hall using the signage in the lobby or by selecting ePosters on the bottom menu. Make sure to leave time to chat with poster presenters.

To view any of today’s non-CME accredited Industry Symposia, please visit the Industry Symposium Auditorium. These are held throughout the meeting, with days and times listed in the program.

IMPORTANT NOTE: We recommend using Google Chrome or Firefox as your internet browser for the best viewing experience. If you are using Internet Explorer you may encounter technical difficulties.

Visit the help desk for any technical or conference-related questions.


You can save sessions and documents to your personalized delegate bag by clicking on the suitcase icon. You can also search for specific sessions or files by using the search bar at the top of the window and save items from here to your delegate bag. We have pre-populated your briefcases with several important items including the program schedule and abstract supplement. You will be able to return to saved items any time until April 30 when the platform closes.

Slides for all presentations will be available in the resource section when watching the presentation.
When viewing the sessions, you can submit questions to the presenters and discussants. Please use the Q&A chat box for scientific questions.

All questions will be addressed during the Live Q&A at the end of the session or if the session doesn’t include a Live Q&A, the presenter will answer the question in the chatbox during the session. Questions are anonymous, so you will not be able to see the questions from other delegates until they are being answered by the presenter through the chat.

You can also leave public comments or chat with other delegates in the session via the public group chat.



Visit the virtual photo booth at the IASLC booth during the #WCLC20 and add your picture to the IASLC mural!

Be sure to download your keepsake image and share on social media tagging us @IASLC using #WCLC20. At the end of the meeting, all images will be created into a powerful mosaic image.




Upcoming Events




Thank You to Our Daily Virtual Tips Sponsors







communications@iaslc.org
Facebook
Twitter

YouTube

LinkedIn


IASLC.org | Conferences and Events | Membership | JTO | JTO CRR
You are receiving this email because you are a member of IASLC, or because you have attended an IASLC event or webinar in the past. You may use the link below titled "Manage Subscriptions" to edit the frequency and types of emails that we send to you, or to unsubscribe. If you unsubscribe from all communications, you may miss important member-related information.

This email was sent to: jojoberner@gmail.com
This email was sent by: IASLC
999 17th Street, Suite 200 Denver, CO 80202 US
We respect your right to privacy - view our policy

Takk igjen!

Veldig interessant artikkel om P.1 mutasjonen som herjer med tidligere coronasyke i Brasil:
https://www.npr.org/sections/goatsandsoda/2021/01/27/961108577/why-scientists-are-very-worried-about-the-variant-from-brazil

Ja da blir det spennende å se pm støtte på 31kr holder i dag eller om den går videre ned.

Covid performance “ranking list”:

https://interactives.lowyinstitute.org/features/covid-performance/

Om du bruker Twitter, så anbefaler jeg å se på oppdateringene til Emma Hodcroft vedrørende oversikt over mutasjoner. Helt fantastisk jobb hun har lagt ned i å vise hvordan mutasjoner utvikler seg over tid, i antall mutasjoner, hvor mutasjonene observeres osv.

Skremmende, men Bemcentinib knekker også mutasjoner’s evne til å feste seg . Jeg gleder meg til nyhetene blir bekreftet.

Tenker at Trond Mohn har lagt inn kjøps ordre på BGBIO ... lukter lunta... 💪

Du finner masse god info på hennes egen web side http://emmahodcroft.com/ også med linker til mye heftig informasjon.

Ja, er lenket fra Twitterkontoen. Fantastisk jobb hun gjør

Du traff godt med salget ditt. Om covid-nyhetene fra BGBIO lar vente på seg, eller er svake resultat, så faller kanskje kursen enda litt til. Da får man billige kreft-aksjer.

he he...jeg liker fokuset på solskinn.

Enn hvis Bergenbio leverer gode covid-resultater fra de fryktede mutasjonsområdene Sør-Afrika og UK.
Det vil gi en finfin PR-effekt.

«Barne-skirenn»

Slik kjennes godt ut - når man får så rett i sine «antagelser»...

Synd at Trond Mohn ikke fikk fylt hele ordren på opp til 1 million aksjer i dag ...Det hadde sikkert passet bra med nyhetene som kommer i natt !

Yngling ØH
Takk for hyggelig innlegg i går kveld. Jeg har vært investert i de fleste Biotech selskap på OSE og er kjent med at risikoen i slike aksjer er betydelig. Potensialet i slike aksjer er det sjelden grunn til å være opptatt av da potensialet er som regel større enn hva noen trenger. Det er alltid risikoen som det er viktig å fokusere på. Biotech aksjer er ofte binære, enten så blir de medisin eller så blir det fiasko og en fiasko melding kan komme over natta. Dette feks ved at det dukker opp konkurrenter som viser resultater man skjønner at man ikke kan matche. Foreløpig så har dette skjedd med to av Radium selskapene på OSE. Når det gjelder BGBIO så tror jeg ikke Godfrey har for vane å vise hvordan de ligger an i forhold til konkurrenter i de ulike indikasjoner, det burde han gjøre. Videre er det slik at jeg har mistet tillitt til Godfrey som du sikkert har sett.

Tidligere var jeg egentlig mest interessert i kreft delen i selskapet. Det har endret seg slik at jeg nå er mest opptatt av Covid biten. Dette på grunn av pandemien og fordi her bør resultater komme først. Kreftbiten er et veldig langt og usikkert løp og mange selskap som jobber med samme indikasjoner.

Dette er noe av det bedre jeg har lest på lenge👍🏼

Focuss, gratulerer med ny inngang i aksjen, ting ser mye bedre ut i dag spesielt Covid 19 delen😉

Gode nyheter fra NSCLC studien!
Ser ut som de har identifisert en gen-signatur som identifiserer hvilke pasienter som kommer til å ha nytte av bemcentinib.

Modning av data fra studien viser fortsatt gode resultater (studien er ikke ferdig ennå). Retningen dette går i, indikerer at vi kan se fortsatt forbedring etter som tiden går.

Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization


Abstract

The Covid-19 pandemic has ravaged the globe, and its causative agent, SARS-CoV-2, continues to rage. Prospects of ending this pandemic rest on the development of effective interventions. Single and combination monoclonal antibody (mAb) therapeutics have received emergency use authorization1,2, with more in the pipeline3–6. Furthermore, multiple vaccine constructs have shown promise7, including two with ~95% protective efficacy against Covid-198,9. However, these interventions were directed toward the initial SARS-CoV-2 that emerged in 2019. Considerable viral evolution has occurred since, including variants with a D614G mutation10 that have become dominant. Viruses with this mutation alone do not appear to be antigenically distinct, however11. Recent emergence of new SARS-CoV-2 variants B.1.1.7 in the UK12 and B.1.351 in South Africa13 is of concern because of their purported ease of transmission and extensive mutations in the spike protein. We now report that B.1.1.7 is refractory to neutralization by most mAbs to the N-terminal domain (NTD) of spike and relatively resistant to a number of mAbs to the receptor-binding domain (RBD). It is modestly more resistant to convalescent plasma (~3 fold) and vaccinee sera (~2 fold). Findings on B.1.351 are more worrisome in that this variant is not only refractory to neutralization by most NTD mAbs but also by multiple individual mAbs to the receptor-binding motif on RBD, largely due to an E484K mutation, although some mAb combinations retain activity. Moreover, B.1.351 is markedly more resistant to neutralization by convalescent plasma (~11-33 fold) and vaccinee sera (~6.5-8.6 fold). B.1.351 and emergent variants14,15 with similar spike mutations present new challenges for mAb therapy and threaten the protective efficacy of current vaccines.

https://www.biorxiv.org/content/10.1101/2021.01.25.428137v2

Altså: vaksinene og antistoffer som er på markedet gir lav immunitet mot Sør-Afrika og Brasil variantene. Noen vaksiner og monoklonale antistoffer som forskerne har testet gir også redusert immunitet mot UK varianten. Dette er i strid med det vaksineselskapene selv forsøker å formidle. De siste dagene har f.eks Pfizer lagt ut noen studier som preprints, som sier at vaksinen er effektiv mot UK varianten, men metodene de har brukt er langt fra så omfattende som blant annet denne studien virker å være.

Hva har dette med BerGenBio å gjøre?

:-) Mye. Om vaksinene ikke virker, så er det høyst relevant for BGBIO.

Vaccinee Sera
Sera were obtained from 12 participants of a Phase 1 clinical trial of Moderna SARS-Co2 mRNA-1273 Vaccine8 conducted at the NIH. These volunteers received two immunizations with the vaccine (100 µg) on days 0 and 28, and blood was collected on day 43. Additional vaccinee sera were obtained at Columbia University Irving Medical Center from 10 health care workers who received the Pfizer BNT162b2 Covid-19 Vaccine at the clinical dose on days 0 and 21. Blood was collected on day 28 or later. Each vaccinee serum sample was assayed for neutralization against UK∆8, SA∆9, and WT pseudoviruses. Fig. 4a shows only a minority of sera to have lost >2-fold neutralizing activity against UK∆8, whereas every sample lost activity against SA∆9, ranging from slight to substantial. These results are quantified and tabulated as fold change in neutralization IC50 titers in Fig. 4b, and the extent of the decline in neutralization activity is more evident in Fig. 4c. Overall, the mean loss of neutralizing activity against UK∆8 appears to be small (1.8 fold, Moderna; 2.0 fold, Pfizer), but quite significant against SA∆9 (8.6 fold, Moderna; 6.5 fold, Pfizer).

Every vaccinee serum was also tested against each single-mutation pseudovirus, and the results are presented in Extended Data Fig. 7 and summarized in Fig. 4b. As was the case for convalescent plasma (Fig. 3b), no single mutation could predictably account for the small loss of serum neutralizing activity against UK∆8. Again, S982A seems to have
a minor negative impact on the plasma neutralizing activity of every serum sample (Fig. 4b), possibly due to distal effects on the RBD (Extended Data Fig. 3c). The loss of neutralizing activity against SA∆9 in vaccinee sera could be principally attributed to E484K (Fig. 4b), indicating that this RBM mutation to be situated in an immunodominant
epitope recognized by all vaccinees studied. Our findings do not reveal any significant differences between the two different vaccines.